Aadi Bioscience, Inc. (AADI)

Aadi Bioscience, Inc. (AADI) Healthcare & Pipeline Overview

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company specializing in precision therapies for genetically defined cancers. Its primary focus is the development and commercialization of FYARRO, an albumin-bound sirolimus formulation, targeting cancers with mTOR pathway gene alterations, including tumor-agnostic indications. The company operates within the dynamic oncology sector, aiming to address specific genetic drivers of cancer.

What Is the Investment Thesis for AADI?

Aadi Bioscience, Inc. presents an investment thesis centered on its lead clinical asset, FYARRO, and its specialized approach to oncology. The company's primary value driver is the successful clinical development and potential commercialization of FYARRO, an albumin-bound sirolimus formulation targeting genetically defined cancers with mTOR pathway alterations. The tumor-agnostic strategy, which focuses on specific genomic alterations rather than tumor origin, represents a significant growth catalyst by potentially expanding the addressable patient population across various cancer types. As a clinical-stage company with a market capitalization of $94.89M and a Beta of 0.34, Aadi Bioscience's valuation is highly sensitive to clinical trial outcomes and regulatory milestones. Upcoming catalysts include data readouts from ongoing clinical evaluations of FYARRO and potential regulatory submissions, which could significantly de-risk the asset and drive value. However, risks include the inherent uncertainties of drug development, potential clinical trial failures, and the highly competitive oncology market. The company's reliance on a single lead candidate also introduces concentration risk, making the success of FYARRO paramount to its long-term prospects.

Based on FMP financials and quantitative analysis

AADI Key Highlights

• Market Capitalization: $0.09 billion, reflecting its status as a clinical-stage biopharmaceutical company.
• Beta: 0.34, indicating lower volatility relative to the broader market, though this can be influenced by its developmental stage.
• Employee Base: A dedicated team of 53 employees focused on precision oncology therapy development.
• Dividend Policy: Currently does not pay a dividend, consistent with a growth-oriented, clinical-stage company reinvesting in R&D.
• Strategic Focus: Specializes in developing precision therapies, with a lead candidate, FYARRO, targeting genetically defined cancers with mTOR pathway alterations.

Who Are AADI's Competitors?

AADI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AADI's Key Strengths?

• Focused expertise in the mTOR pathway and precision oncology.
• Lead drug candidate, FYARRO, with a novel albumin-bound sirolimus formulation.
• Strategic pursuit of tumor-agnostic indications for broader patient applicability.
• Dedicated team of 53 employees focused on specialized drug development.

What Are AADI's Weaknesses?

• Reliance on a single lead drug candidate (FYARRO) for future revenue.
• Clinical-stage company with no current commercialized products or revenue.
• Small market capitalization ($0.09B) and limited financial resources compared to larger competitors.
• High inherent risks associated with biopharmaceutical drug development, including potential for clinical trial failures.

What Could Drive AADI Stock Higher?

• Potential submission of regulatory applications for FYARRO in target indications, marking a critical step towards commercialization.
• Continued progress and data readouts from clinical evaluations of FYARRO for genetically defined cancers with mTOR pathway activation.
• Initiation of new clinical trials or expansion into additional tumor-agnostic indications for FYARRO, broadening its potential market.
• Strategic advancements in manufacturing and supply chain development to support future commercialization of FYARRO.
• Potential for securing strategic partnerships or collaborations to bolster development and commercialization efforts for FYARRO.

What Are the Key Risks for AADI?

• Financial-distress signal — its Altman Z-Score of -1.00 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-79.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• High dependence on the successful clinical development, regulatory approval, and commercialization of a single lead drug candidate, FYARRO.
• Risk of clinical trial failures, delays, or unexpected adverse events that could halt or significantly impede FYARRO's development.
• Intense competition within the precision oncology market from established pharmaceutical companies and other biotech firms developing similar or alternative therapies.
• Inability to secure adequate funding to sustain extensive research and development activities and clinical trials for FYARRO.
• Regulatory hurdles, including the possibility of not receiving necessary approvals or facing extended review periods from health authorities.

What Are the Growth Opportunities for AADI?

• Successful Clinical Development and Commercialization of FYARRO: The primary growth driver for Aadi Bioscience is the successful progression of its lead drug candidate, FYARRO, through clinical trials and subsequent regulatory approval. FYARRO, an albumin-bound sirolimus, targets cancers with mTOR pathway activation. Successful clinical outcomes demonstrating efficacy and safety could lead to regulatory approvals, opening up significant market opportunities. The global oncology market is projected to reach over $300 billion by 2027, with targeted therapies forming a substantial and growing segment. Achieving market authorization for FYARRO would transition Aadi from a clinical-stage company to a commercial one, unlocking revenue generation potential within the next 3-5 years, contingent on trial success and regulatory timelines.
• Expansion into Additional Tumor-Agnostic Indications: Aadi Bioscience's strategy includes evaluating FYARRO in tumor-agnostic indications, targeting specific genomic alterations that activate the mTOR pathway regardless of tumor origin. This approach allows for broader applicability beyond a single cancer type. Expanding the approved indications for FYARRO based on its mechanism of action could significantly enlarge the addressable patient population. The market for tumor-agnostic therapies is emerging, driven by advancements in genomic sequencing and precision oncology. Each new approved indication represents a distinct market segment, potentially adding hundreds of millions to billions in peak sales opportunity over the next 5-10 years, depending on the prevalence of the targeted genetic alterations.
• Regulatory Approvals for FYARRO: Securing regulatory approvals from health authorities like the FDA or EMA is a critical growth catalyst for Aadi Bioscience. The successful navigation of the regulatory pathway for FYARRO in its targeted indications would validate its clinical efficacy and safety profile, allowing the company to commercialize the drug. Regulatory approval not only enables market entry but also significantly enhances the company's credibility and attractiveness to potential partners and investors. The timeline for regulatory approval typically spans 1-3 years post-submission, and successful approval would unlock access to the multi-billion dollar oncology market for precision therapies, transforming Aadi's revenue potential.
• Market Penetration and Adoption of FYARRO Post-Approval: Following regulatory approval, Aadi Bioscience's growth will be driven by its ability to effectively penetrate the market and achieve widespread adoption of FYARRO among oncologists and patients. This involves establishing robust commercial infrastructure, engaging in targeted marketing and sales efforts, and securing favorable reimbursement policies. The success of market penetration will depend on the drug's clinical profile, competitive landscape, and pricing strategy. Effective commercialization could lead to significant revenue streams, contributing to the company's financial growth over the next 5-10 years as it captures market share in its specific oncology niches.
• Continued Research and Development in mTOR Pathway Oncology: Aadi Bioscience's core expertise lies in the mTOR pathway and its role in cancer. Continued investment in research and development within this specific area could lead to further insights, potentially identifying new therapeutic targets or optimizing existing treatments. While FYARRO is the current focus, sustained R&D efforts could lay the groundwork for future pipeline candidates or enhancements to FYARRO's utility. This ongoing commitment to scientific advancement ensures the company remains at the forefront of mTOR-driven cancer research, positioning it for long-term innovation and potential future drug development, likely impacting growth over a 5-15 year horizon.

What Opportunities Does AADI Have?

• Successful clinical trial outcomes and regulatory approvals for FYARRO.
• Expansion of FYARRO into additional genetically defined or tumor-agnostic indications.
• Addressing significant unmet medical needs in specific cancer patient populations.
• Potential for strategic partnerships to accelerate development and commercialization.

What Threats Does AADI Face?

• Failure of clinical trials to demonstrate efficacy or safety for FYARRO.
• Intense competition from other oncology drug developers, including larger pharmaceutical companies.
• Stringent regulatory hurdles and potential delays in drug approval processes.
• Funding challenges and the need for significant capital to sustain R&D efforts.

What Are AADI's Competitive Advantages?

• Proprietary lead drug candidate, FYARRO, an albumin-bound sirolimus formulation.
• Specialized focus on the mTOR pathway, a critical and well-defined oncogenic driver.
• Clinical-stage development progress with FYARRO in specific cancer indications.
• Potential for tumor-agnostic approvals, broadening market reach based on genetic markers.

What Does AADI Do?

Aadi Bioscience, Inc., established in 2007 and headquartered in Pacific Palisades, California, operates as a clinical-stage biopharmaceutical company dedicated to the development and commercialization of precision therapies. The company's strategic focus lies in addressing genetically defined cancers characterized by alterations within the mTOR pathway genes. This pathway is a critical regulator of cell growth, proliferation, and survival, and its dysregulation is implicated in various oncological conditions. Aadi Bioscience aims to leverage a targeted approach to cancer treatment, moving beyond traditional chemotherapy to therapies that specifically interfere with the molecular mechanisms driving tumor growth. Its market position is defined by its specialized focus on a specific genetic pathway, differentiating it within the broader oncology landscape. The cornerstone of Aadi Bioscience's pipeline is its lead drug candidate, FYARRO (sirolimus albumin-bound nanoparticles for injectable suspension). FYARRO represents an innovative formulation of sirolimus, an mTOR inhibitor, delivered via albumin-bound nanoparticles. This unique delivery mechanism is designed to enhance drug distribution and efficacy while potentially mitigating some of the systemic toxicities associated with conventional mTOR inhibitors. The company is actively evaluating FYARRO across a spectrum of cancers where mTOR pathway activation is known to play a role. This includes not only specific tumor types but also tumor-agnostic indications, meaning the therapy targets specific genomic alterations that activate the mTOR pathway regardless of the tumor's origin. This tumor-agnostic strategy positions Aadi Bioscience at the forefront of personalized medicine, aiming to provide treatments based on a patient's genetic profile rather than solely on the anatomical location of the cancer. With a team of 53 employees, Aadi Bioscience is committed to advancing its clinical programs to bring these precision therapies to patients with significant unmet medical needs.

What Products and Services Does AADI Offer?

• Develops precision therapies for genetically defined cancers.
• Focuses on cancers with alterations in mTOR pathway genes.
• Advances FYARRO, an albumin-bound sirolimus formulation, as its lead drug candidate.
• Evaluates FYARRO in various cancers with known mTOR pathway activation.
• Pursues tumor-agnostic indications, targeting specific genomic alterations.
• Engages in clinical-stage biopharmaceutical research and development.
• Aims to commercialize innovative oncology treatments.

How Does AADI Make Money?

• Conducts clinical research and development to advance drug candidates like FYARRO.
• Seeks regulatory approvals for its precision oncology therapies.
• Aims to generate revenue through the commercialization and sale of approved drugs.
• Potentially explores licensing agreements or partnerships for drug development and distribution.

What Industry Does AADI Operate In?

Aadi Bioscience, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on oncology. The broader healthcare sector is experiencing a significant shift towards precision medicine, where treatments are tailored to a patient's genetic profile or specific molecular pathways driving their disease. Aadi's strategy aligns directly with this trend by developing therapies for genetically defined cancers with mTOR pathway alterations. The oncology market is one of the largest and fastest-growing therapeutic areas, driven by an aging global population and advancements in understanding cancer biology. However, it is also characterized by high R&D costs, lengthy clinical development timelines, and intense competition from numerous pharmaceutical and biotech companies. Aadi Bioscience, as a clinical-stage entity, positions itself by targeting a specific, well-understood pathway (mTOR) with a novel formulation (albumin-bound sirolimus), aiming to carve out a niche within this dynamic landscape. The success of its lead candidate, FYARRO, will be critical in establishing its competitive standing and market relevance against established players and other emerging precision oncology firms.

Who Are AADI's Key Customers?

• Patients suffering from genetically defined cancers with mTOR pathway alterations.
• Oncologists and healthcare providers who prescribe and administer cancer therapies.
• Hospitals and cancer treatment centers.
• Potentially, pharmaceutical partners for co-development or commercialization.

ROE -80%Key Financial Metrics

Return on equity for Aadi Bioscience, Inc. stands at -79.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -91.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -43.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -36.5%, the inverse of the P/E and a quick read on earnings relative to price.

Aadi Bioscience, Inc. (AADI) Valuation Context

Valued at $94.89M, AADI is classified as a micro-cap stock. Relative to its peer group, AADI's quantitative score of 50/100 is below the peer average of 76/100.

Company Profile

Aadi Bioscience, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pacific Palisades, US. The company is led by CEO David J. Lennon. AADI has traded publicly since 2018.

F-Score 1/9Financial Health

Aadi Bioscience, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.00 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Aadi Bioscience, Inc. revenue of about $14.9M for fiscal 2026, with EPS near $-0.95.

Net buyingInsider Activity

The most recent 12 insider filings for Aadi Bioscience, Inc. break down as 5 sales and 7 purchases. On net that is roughly 5.3M shares acquired (about $12.5M) — insiders putting money in tends to read as conviction.

AADI Financials

AADI Latest News

No recent news available for AADI.

AADI Analyst Consensus

AADI MoonshotScore

What Investors Ask About Aadi Bioscience, Inc. (AADI) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources